Special Issue "The Clinical Outcomes of Inflammatory Disease: The Pharmaceutical Perspective"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 714

Special Issue Editors

College of Pharmacy, Dongduk Women’s University, Seoul, Republic of Korea
Interests: drug–drug interaction; drug–food interaction; pharmacovigilance; drug use evaluation; pharmacoepidemiology
Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea
Interests: drug use evaluation; pharmacy education; medication safety
College of Pharmacy, Dongduk Women’s University, Seoul 02748, Republic of Korea
Interests: photodynamic therapy; cancer treatment; drug delivery system
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recently, it was revealed that inflammation appears as a complex process in the immune system, and it has been found to be related to cardiovascular disease, cancer, systemic infection, and systemic inflammatory diseases. Thus, if many drugs were used to simply treat and/or control the patient's symptoms in the past, recent approaches to suppress or prevent inflammation have been suggested, and attention is paid to the fact that inflammation plays a major role in the patient's clinical prognosis.

This Special Issue aims to present various treatment strategies in treating or preventing diseases related to inflammation. In particular, it was planned to present research results that can improve clinical outcome and efficacy, and can minimize adverse effects and drug interactions. We welcome all articles related to pharmaceutical care services in inflammatory diseases (status).

Dr. Kiyon Rhew
Dr. Young Sook Lee
Dr. Ji-Eun Chang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • inflammation
  • inflammatory disease
  • immune system
  • clinical efficacy for inflammatory condition
  • drug-drug interaction
  • drug-disease interaction

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Repurposing Niclosamide as a Therapeutic Drug against Acute Liver Failure by Suppressing Ferroptosis
Pharmaceutics 2023, 15(7), 1950; https://doi.org/10.3390/pharmaceutics15071950 - 14 Jul 2023
Viewed by 568
Acute liver failure (ALF) is a severe liver disease with a high mortality rate without effective therapeutic drugs. Ferroptosis is a form of programmed cell death that plays an important role in ALF. In this study, we aimed to identify ferroptosis-related genes in [...] Read more.
Acute liver failure (ALF) is a severe liver disease with a high mortality rate without effective therapeutic drugs. Ferroptosis is a form of programmed cell death that plays an important role in ALF. In this study, we aimed to identify ferroptosis-related genes in ALF, thereby predicting promising compounds to treat ALF. First, mRNA microarray data were utilized to identify the ferroptosis-related differentially expressed genes (DEGs). Hub genes were screened in the protein–protein interaction network and validated. Subsequently, potential drugs to treat ALF were predicted. One of the predicted drugs was tested in an ALF model of mice. Ferroptosis examination and molecular docking were analyzed to explore the mechanism. A total of 37 DEGs were identified, ten hub genes were extracted, and their expression in ALF was validated. The predicted drug niclosamide mitigated lipopolysaccharide/D-galactosamine-induced hepatotoxicity, and decreased mortality of mice in the ALF model. Mechanically, niclosamide may combine with signal transducer and activator of transcription 3 to inhibit ALF progression by suppressing ferroptosis. This study may help advance our understanding of the role of ferroptosis in ALF, and niclosamide may be promising for therapeutic efficacy in patients with ALF. Full article
Show Figures

Figure 1

Back to TopTop